Moderna Shares Slip After EMA Backs mCOMBRIAX Flu-COVID Combo Vaccine on February 27, 2026

On February 27, 2026, Moderna's stock fluctuated as the European Medicines Agency's CHMP issued a positive opinion for mCOMBRIAX, its combination influenza and COVID-19 vaccine for adults 50 and older. The shares initially spiked but then traded at $51.06, down 1.27% in early U.S. trading, even as Phase 3 data supported the recommendation and analysts remained divided on the company's outlook.